Hookipa Pharma Inc (NASDAQ:HOOK – Get Rating) has been given an average recommendation of “Buy” by the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.
A number of research firms have issued reports on HOOK. Zacks Investment Research lowered Hookipa Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, February 10th. Royal Bank of Canada cut their target price on Hookipa Pharma from $11.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, March 25th. SVB Leerink raised their target price on Hookipa Pharma from $3.00 to $4.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 16th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Hookipa Pharma in a research report on Friday, March 25th. Finally, Truist Financial cut their target price on Hookipa Pharma from $23.00 to $16.00 in a research report on Wednesday, February 16th.
A number of large investors have recently added to or reduced their stakes in HOOK. Bank of America Corp DE grew its stake in Hookipa Pharma by 1,378.9% during the 4th quarter. Bank of America Corp DE now owns 719,931 shares of the company’s stock worth $1,678,000 after buying an additional 671,251 shares during the last quarter. Redmile Group LLC grew its stake in Hookipa Pharma by 29.3% during the 4th quarter. Redmile Group LLC now owns 2,385,136 shares of the company’s stock worth $5,557,000 after buying an additional 540,831 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Hookipa Pharma during the 4th quarter worth approximately $915,000. Acadian Asset Management LLC grew its stake in Hookipa Pharma by 210.5% during the 4th quarter. Acadian Asset Management LLC now owns 252,256 shares of the company’s stock worth $587,000 after buying an additional 171,019 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Hookipa Pharma by 15.1% in the 4th quarter. BlackRock Inc. now owns 1,212,502 shares of the company’s stock valued at $2,825,000 after purchasing an additional 158,988 shares during the last quarter. Hedge funds and other institutional investors own 57.65% of the company’s stock.
Hookipa Pharma (NASDAQ:HOOK – Get Rating) last posted its quarterly earnings results on Thursday, March 24th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). The company had revenue of $3.90 million during the quarter, compared to analyst estimates of $4.31 million. Hookipa Pharma had a negative net margin of 410.15% and a negative return on equity of 65.28%. During the same period in the prior year, the business earned ($0.46) EPS. On average, research analysts forecast that Hookipa Pharma will post -1.64 earnings per share for the current year.
Hookipa Pharma Company Profile (Get Rating)
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
- Get a free copy of the StockNews.com research report on Hookipa Pharma (HOOK)
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- Landstar Systems Stock Can Bottom Down Here
- 3M Stock is Worth a Look Because of the Company it Keeps
- 3 Attractive Mid Cap Swing Trades
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.